Introduction:

Cannabis Sativa L. products are known to be therapeutically effective since ancient times, despite its pharmacological typification was made in the mid-20th century. Its use was recently regulated in Uruguay.

Objective:

to analyse a preliminary clinical-therapeutic experience with MC with high content of cannabidiol (CBD).

Method:

epidemiological, observational and retrospective study of a 355 patient cohort who spontaneously consulted to learn about CM at a private clinic, between August 2016 and December 2017.

Demographic data, medical records, expectation and previous experience with cannabis were collected in the first interview. In most cases, cannabis with high content of CBD was prescribed (5,25 % CBD and 0,2% THC).

In subsequent consultations, access to access to MC was invesrtigated and both response to it and adverse effects were studied by means of analogue scales. The study used descriptive statistics.

Results:

in the cohort studied, women with an average age of 67 years old and university studies prevailed. The following conditions motivated consultations: neurological (38%), rheumatic or bone degenerative diseases (37%), neoplasms (13%), psychiatric diseases (4%) and miscelánea (8%). In most cases (60,6%) patients stated symptoms improved and only 16,3% of the populaiton studied presented mild adverse effects. High costs and difficulties in accessing MC were the reasons for not starting or abandoning treatment.

Conclusions:

our preliminary study reflects the positive therapeutic response and non significant adverse effects to MC with high content of CBD. 60,6% of patients treated referred improvement in their symptoms. Decisive factors for a successful treatment point at the need to make access to MC easier by improving management to obtain it and reducing costs for a greater accessibility.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )